I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

The regional Stoxx 600 index is down 0.18%, with France's CAC 40 and Germany's DAX lower by 0.43% and 0.22%, respectively.

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...